- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03592966
Investigating the Acute Effects of Blueberry (Poly)Phenols on Vascular Function and Cognition in Healthy Individuals. (BluLife)
May 18, 2021 updated by: Dr Ana Rodriguez-Mateos, King's College London
Randomised, Double-blind, Placebo Controlled, Crossover Trial Investigating the Acute Effects of Blueberry (Poly)Phenols on Vascular Function and Cognitive Performance in Healthy Individuals Across the Life Course.
This study aims to determine the effect of blueberry (poly)phenol vs placebo on vascular function and cognitive performance with an insight into cerebral blood flow velocity changes, across all ages of the general healthy population.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Foods rich in certain (poly)phenols, particularly flavonoids, such as berries, have been shown to improve measures of vascular function as well as cognitive performance in human intervention studies.
Blueberries are rich in anthocyanins, a subclass of flavonoids that have been widely linked to health benefits, particularly improvements in endothelial function.
Research have previously shown that blueberries improve executive functioning and memory in both healthy adults and children.
These improvements were seen within 2-5 hours post-consumption of blueberries, a time-course that positively correlates with improvements in vascular function (measured as flow-mediated dilation).
This indicates that increases in blood flow may influence improvements in cognitive performance.
To date no study has investigated whether blueberry consumption can induce an increase in cerebral blood flow, with subsequent improvements in vascular and cognitive function.
In this study, investigators aim to directly link wild blueberry consumption with increased vascular and cerebral blood flow and positive cognitive outcomes in healthy individuals through the life course, between the ages of 8 and 80 years old.
Investigators will use a large group of healthy subjects representative of the general public over a wide age range in males and females to evaluate the generalisability of the health benefits of blueberry consumption.
Study Type
Interventional
Enrollment (Actual)
92
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom, SE1 9NH
- King's College London
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 years to 80 years (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion criteria:
- Healthy men and women aged 8-80 years old
- Are able to understand the nature of the study
- Able and willing to give signed written informed consent with the addition of a parent/carer for the consent of children under 16.
- Are willing to maintain their normal eating/drinking habits and exercise habits to avoid changes in body weight over the duration of the study.
Exclusion Criteria:
- Manifest cardiovascular diseases including coronary artery disease, cerebrovascular disease and peripheral artery disease.
- Hypertensive, as defined as SBP superior or equal to 140 mmHg or DBP superior or equal to 90 mmHg.
- Obese participants, defined as BMI superior or equal to 30.
- Diabetes mellitus and metabolic syndrome.
- Acute inflammation, terminal renal failure or malignancies.
- Abnormal heart rhythm (lower or higher than 60-100 bpm).
- Allergies to berries or another significant food allergy.
- Subjects under medication or on vitamin/dietary supplements (within 2 weeks of baseline).
- Subjects who have lost more than 10% of their weight in the past 6 months or are currently on a diet.
- Subjects who reported participant in another study within one month before the study starts.
- Subjects who smoke cigarettes.
- MCI or dyslexic or unable to complete the cognitive function tasks for any reason such as visual impairments.
- Subjects who require chronic antimicrobial or antiviral treatment.
- Subjects with unstable psychological condition.
- Subjects with history of cancer, myocardial infarction, cerebrovascular incident.
- Any reason or condition that in the judgment of the clinical investigator(s) may put the subject at unacceptable risk or that may preclude the subject from understanding or complying with the study's requirements.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Placebo
Freeze-dried placebo powder
|
Freeze-dried placebo powder
|
|
ACTIVE_COMPARATOR: Wild Blueberry powder
Freeze-dried whole fruit blueberry drink.
|
Freeze-dried whole fruit blueberry drink.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cognitive function
Time Frame: Change from baseline cognitive function at 2 hours post-consumption
|
Cognitive testing involves the participant conducting tasks administered on a tablet-style laptop.
The participants will be conducting these tasks whilst cerebral blood flow measurements are taking place.
The cognitive testing battery will consist of 4 tasks including a mood assessment (PANAS).
|
Change from baseline cognitive function at 2 hours post-consumption
|
|
Endothelial Function
Time Frame: Change from baseline endothelial function at 2 hours post-consumption
|
Flow mediated dilation (FMD)
|
Change from baseline endothelial function at 2 hours post-consumption
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cerebral blood flow (CBF)
Time Frame: Change of baseline cerebral blood flow at 2 hours post consumption
|
Trans-cranial blood flow will be assessed by Non-imaging transcranial Doppler sonography (TCD)
|
Change of baseline cerebral blood flow at 2 hours post consumption
|
|
Blood pressure
Time Frame: Change from baseline systolic blood pressure at 2 hours post consumption
|
Automated clinical digital sphygmomanometer
|
Change from baseline systolic blood pressure at 2 hours post consumption
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plasma blueberry (poly)phenol metabolites
Time Frame: 2 hours
|
Measured by liquid chromotography- mass spectrometry (LC/MS)
|
2 hours
|
|
Urine (poly)phenol metabolites
Time Frame: Baseline and 12 weeks
|
24-hour urine samples
|
Baseline and 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 1, 2018
Primary Completion (ACTUAL)
October 1, 2020
Study Completion (ACTUAL)
May 18, 2021
Study Registration Dates
First Submitted
April 6, 2018
First Submitted That Met QC Criteria
July 18, 2018
First Posted (ACTUAL)
July 19, 2018
Study Record Updates
Last Update Posted (ACTUAL)
May 19, 2021
Last Update Submitted That Met QC Criteria
May 18, 2021
Last Verified
May 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- BLULIFE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
University of Vermont Medical CenterAvocado Nutrition CenterRecruitingHealthy | Healthy Volunteers | Healthy Subjects | Healthy Volunteer | Healthy Adult | Healthy Volunteers Only | Healthy Male and Female Subjects | Healthy Non-smokersUnited States
-
Dragonfly TherapeuticsRecruitingHealthy | Healthy Participants | Healthy Adult Females | Volunteer | Healthy Adult MaleAustralia
-
University of PalermoCompletedHealthy | Healthy Volunteers | Healthy Subjects | Healthy Participants | Static Stretching | Stretch | StretchingItaly
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Umm Al-Qura UniversityActive, not recruitingHealthy | Healthy Participants | Healthy Adult | Healthy Women | Healthy Adult Females | Healthy Adult Participants | Healthy Young Adults | Healthy Adult Female Participants | Healthy Adult Male | Poor Sleep Quality | Healthy (Controls) | Poor Sleeping Quality | Healthy Adult Male Subjects | Health Adult SubjectsSaudi Arabia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
University of PalermoCompletedHealthy Participants | Healthy Adult Participants | Healthy Young AdultsItaly
-
PfizerNot yet recruitingHealthy | Healthy AdultsUnited States
-
RAGE BioRecruitingHealthy | Healthy SmokerAustralia
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States